Alison Shelley Witkin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 10 | 2023 | 2543 | 1.490 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 615 | 0.870 |
Why?
|
| Ventricular Pressure | 2 | 2019 | 204 | 0.760 |
Why?
|
| Hospital Rapid Response Team | 1 | 2017 | 54 | 0.560 |
Why?
|
| Cardiac Output | 1 | 2019 | 838 | 0.530 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2015 | 334 | 0.460 |
Why?
|
| Pulmonary Artery | 4 | 2022 | 1921 | 0.400 |
Why?
|
| Hypertension, Pulmonary | 3 | 2022 | 1570 | 0.400 |
Why?
|
| Thrombolytic Therapy | 2 | 2017 | 2108 | 0.370 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 2 | 2022 | 141 | 0.330 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1300 | 0.280 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2024 | 1459 | 0.210 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3340 | 0.200 |
Why?
|
| Endarterectomy | 2 | 2018 | 195 | 0.180 |
Why?
|
| Dyspnea | 3 | 2023 | 1353 | 0.180 |
Why?
|
| Hyperammonemia | 1 | 2020 | 77 | 0.160 |
Why?
|
| Exercise Test | 2 | 2023 | 2128 | 0.160 |
Why?
|
| Pneumothorax | 1 | 2022 | 379 | 0.150 |
Why?
|
| Myositis | 1 | 2021 | 269 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2023 | 805 | 0.150 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2017 | 30 | 0.150 |
Why?
|
| Embolectomy | 1 | 2017 | 129 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2019 | 2511 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 397 | 0.140 |
Why?
|
| Learning Curve | 1 | 2017 | 231 | 0.130 |
Why?
|
| Aneurysm | 1 | 2018 | 337 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 911 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 830 | 0.100 |
Why?
|
| Acute Disease | 2 | 2022 | 7268 | 0.100 |
Why?
|
| Patient Selection | 1 | 2024 | 4279 | 0.100 |
Why?
|
| Medical History Taking | 1 | 2015 | 773 | 0.100 |
Why?
|
| Aftercare | 1 | 2017 | 916 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 498 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2020 | 1302 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2023 | 3905 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2023 | 12968 | 0.090 |
Why?
|
| Perfusion Imaging | 2 | 2022 | 196 | 0.090 |
Why?
|
| Echocardiography | 2 | 2020 | 4981 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 1469 | 0.080 |
Why?
|
| Decision Making | 2 | 2024 | 3925 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2022 | 9288 | 0.080 |
Why?
|
| Internal Medicine | 1 | 2015 | 1048 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2017 | 2985 | 0.070 |
Why?
|
| Disease Progression | 3 | 2023 | 13505 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2514 | 0.070 |
Why?
|
| Humans | 22 | 2024 | 760613 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2022 | 80345 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 1864 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14661 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7408 | 0.050 |
Why?
|
| Supreme Court Decisions | 1 | 2023 | 133 | 0.050 |
Why?
|
| Curriculum | 1 | 2015 | 3718 | 0.050 |
Why?
|
| Prone Position | 1 | 2022 | 196 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5325 | 0.050 |
Why?
|
| Ammonia | 1 | 2020 | 236 | 0.040 |
Why?
|
| Edema | 1 | 2022 | 770 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 415 | 0.040 |
Why?
|
| Middle Aged | 7 | 2024 | 220359 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2023 | 830 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 418 | 0.040 |
Why?
|
| Male | 9 | 2024 | 359718 | 0.040 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2020 | 200 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 607 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 568 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 865 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 1131 | 0.030 |
Why?
|
| Female | 8 | 2024 | 391246 | 0.030 |
Why?
|
| Aged | 4 | 2024 | 169143 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2015 | 5870 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 29661 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2022 | 2141 | 0.030 |
Why?
|
| Lung | 2 | 2023 | 9994 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 2167 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20509 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2018 | 1108 | 0.020 |
Why?
|
| Syndrome | 1 | 2018 | 3280 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2622 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2017 | 1479 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4193 | 0.020 |
Why?
|
| Young Adult | 3 | 2023 | 58748 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1544 | 0.020 |
Why?
|
| Biopsy | 1 | 2022 | 6771 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 3200 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2019 | 1196 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 41337 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 74333 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2022 | 4897 | 0.020 |
Why?
|
| Adult | 4 | 2024 | 220007 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 8483 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 6476 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14494 | 0.010 |
Why?
|
| Quality of Life | 1 | 2023 | 13308 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 64981 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2024 | 54306 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24102 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40139 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 58980 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36286 | 0.010 |
Why?
|